The difference in MIP selectivity between non-cancerous cells and cancer cells may be due to differences in growth rate, which results from the presence of distinct cell surface receptors, differences in the uptake of certain drugs and the method used for assessment of toxicity16. Here, CD177 is linked to cancer.